Figure 2
Figure 2. Roquinsan/+ mouse develop asymmetric lymphoadenopathy and splenomegaly. (A) Comparison of enlarged cervical and inguinal lymph nodes with the contralateral normal lymph node in a Roquinsan/+ female mouse. (B) Representative diagram of spleens from 5 Roquinsan/+ and 4 Roquin+/+ control age-matched mice. *Mice with lymphadenopathy. (C) Spleen weights of Roquinsan/+ mice separated into those with and without lymphadenopathy compared with Roquin+/+ controls. Mice were 18 to 40 weeks of age. (D) Total serum IgG titres assayed by ELISA. Roquinsan/+ mice with lymph node tumors have a statistically significant increase in serum IgG titres compared with nontumor Roquinsan/+ mice: *P < .05; **P < .01.

Roquinsan/+ mouse develop asymmetric lymphoadenopathy and splenomegaly. (A) Comparison of enlarged cervical and inguinal lymph nodes with the contralateral normal lymph node in a Roquinsan/+ female mouse. (B) Representative diagram of spleens from 5 Roquinsan/+ and 4 Roquin+/+ control age-matched mice. *Mice with lymphadenopathy. (C) Spleen weights of Roquinsan/+ mice separated into those with and without lymphadenopathy compared with Roquin+/+ controls. Mice were 18 to 40 weeks of age. (D) Total serum IgG titres assayed by ELISA. Roquinsan/+ mice with lymph node tumors have a statistically significant increase in serum IgG titres compared with nontumor Roquinsan/+ mice: *P < .05; **P < .01.

Close Modal

or Create an Account

Close Modal
Close Modal